Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial
Authors:
- Brigitte Tardy-PoncetBTBrigitte Tardy-Poncet
- Philippe NguyenPNPhilippe Nguyen
- Jean-Claude ThiranosJTJean-Claude Thiranos
- Pierre-Emmanuel MorangePMPierre-Emmanuel Morange
- Christine Biron-AndréaniCBChristine Biron-Andréani
- Yves GruelYGYves Gruel
- Jérome MorelJMJérome Morel
- Alain WynckelAWAlain Wynckel
- Lelia GrunebaumLGLelia Grunebaum
- Judith Villacorta-TorresJVJudith Villacorta-Torres
- Sandrine GrosjeanSGSandrine Grosjean
- Emmanuel de MaistreEMEmmanuel de Maistre
Open Access
- 1 December 2015
- journal article
- clinical trial
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 396
Abstract
Introduction: The aim of this study was to collect data in France in patients with heparin-induced thrombocytopenia who required parenteral anticoagulation and for whom other non-heparin anticoagulant therapies were contraindicated including patients with renal failure, cross-reactivity to danaparoid or at high hemorrhagic risk.Methods: A total of 20 patients, of mean age 72 ± 10 years, were enrolled in this open-label, multicenter clinical study. Exploratory statistical data analysis was performed with descriptive interpretation of intra-individual comparisons using simple univariate statistics.Results: The diagnosis of HIT was confirmed in 16 subjects by an independent scientific committee. Fourteen patients (70 %) were in an intensive care unit during the course of the study. Patients were treated with argatroban for a mean duration of 8.5 ± 6.1 days. The mean starting dose of argatroban was 0.77 ± 0.45 μg/kg/min. Platelet recovery was rapid.aPTT and anti-IIa activity assays were used to monitor the dose of argatroban. The mean baseline aPTT value was 45.0 ± 9.8 sec and increased to 78.2 ± 35.8 sec two hours after initiating argatroban. At this time mean argatroban concentration was 0.34 ± 0.16 and 0.61 ± 0.28 μg/ml using ECT and TT measurements, respectively. New and/or extended thromboses were reported in 25 % of patients and major bleedings were documented in 15 %. Six patients died due to their underlying medical condition.Conclusion: Considering its hepatic elimination and its short half-life, argatroban can be considered as a safe therapeutic option in HIT patients at high hemorrhagic risk and with renal failure, particularly in an ICU setting.Keywords
This publication has 28 references indexed in Scilit:
- Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy – A European PerspectiveThrombosis Research, 2012
- High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: A case report and review of laboratory considerationsAmerican Journal of Health-System Pharmacy, 2012
- Treatment and Prevention of Heparin-Induced ThrombocytopeniaChest, 2012
- Practical Viewpoints on the Diagnosis and Management of Heparin-Induced ThrombocytopeniaSeminars in Thrombosis and Hemostasis, 2011
- Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective studyCritical Care, 2010
- Argatroban Anticoagulation in Renal Dysfunction: A Literature AnalysisNephron Clinical Practice, 2008
- Monitoring direct thrombin inhibitors with a plasma diluted thrombin timeThrombosis and Haemostasis, 2007
- Heparin-induced thrombocytopenia (HIT)Thrombosis and Haemostasis, 2006
- Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting TimeThrombosis and Haemostasis, 2004
- The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin InhibitorsPathophysiology of Haemostasis and Thrombosis, 2003